NEWS
New Feature!!!! University Subject Rankings in 12 branches
FOR SCIENTIST REGISTRATION FOR INSTITUTIONAL BULK REGISTRATION
FOR EDIT YOUR UNIVERSITY / INSTITUTION PAGE
Some differences of the AD Scientific Index
New Feature!!!! University Subject Rankings in 12 branches
List without CERN, Statistical Data etc. Only in AD Scientific Index
New Feature!!!! University Subject Rankings in 12 branches
AD
Scientific Index 2024
About Us
Methodology
Compare & Choose
Contact - FAQ
login
Login
person_add
Register
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
school
University Rankings
subject
University Subject Rankings
insights
Subject Rankings
place
Country Rankings
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
local_fire_department
Country Top Lists
Daniel Yc Heng
University of Calgary - Calgary / Canada
Others
AD Scientific Index ID: 4923180
Edit Form
Registration, Add Profile,
Premium Membership
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Congresses (0)
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Daniel Yc Heng's MOST POPULAR ARTICLES
1-)
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a large …DYC Heng, W Xie, MM Regan, MA Warren, AR Golshayan, C Sahi, ...Journal of clinical oncology 27 (34), 5794-5799, 200919932009
2-)
Renal cell carcinomaJJ Hsieh, MP Purdue, S Signoretti, C Swanton, L Albiges, M Schmidinger, ...Nature reviews Disease primers 3 (1), 1-19, 201715632017
3-)
Cabozantinib versus everolimus in advanced renal-cell carcinomaTK Choueiri, B Escudier, T Powles, PN Mainwaring, BI Rini, F Donskov, ...New England Journal of Medicine 373 (19), 1814-1823, 201510902015
4-)
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based studyDYC Heng, W Xie, MM Regan, LC Harshman, GA Bjarnason, ...The lancet oncology 14 (2), 141-148, 201310572013
5-)
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trialTK Choueiri, B Escudier, T Powles, NM Tannir, PN Mainwaring, BI Rini, ...The lancet oncology 17 (7), 917-927, 201610542016
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept